These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19929710)

  • 1. Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
    Danis RP; Sheetz MJ
    Expert Opin Pharmacother; 2009 Dec; 10(17):2913-25. PubMed ID: 19929710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruboxistaurin: LY 333531.
    Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
    Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats.
    Wei L; Sun D; Yin Z; Yuan Y; Hwang A; Zhang Y; Si R; Zhang R; Guo W; Cao F; Wang H
    Apoptosis; 2010 Apr; 15(4):488-98. PubMed ID: 20044781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    ; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP;
    Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKC inhibition and diabetic microvascular complications.
    Clarke M; Dodson PM
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.
    Brooks B; Delaney-Robinson C; Molyneaux L; Yue DK
    J Diabetes Complications; 2008; 22(2):88-95. PubMed ID: 18280438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
    Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
    Tuttle KR; McGill JB; Haney DJ; Lin TE; Anderson PW;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):631-6. PubMed ID: 17699475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
    Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
    Aiello LP; Clermont A; Arora V; Davis MD; Sheetz MJ; Bursell SE
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD; Sheetz MJ; Aiello LP; Milton RC; Danis RP; Zhi X; Girach A; Jimenez MC; Vignati L;
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C inhibitors in the treatment of diabetic retinopathy. Review.
    Gálvez MI
    Curr Pharm Biotechnol; 2011 Mar; 12(3):386-91. PubMed ID: 20939796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease.
    Kelly DJ; Edgley AJ; Zhang Y; Thai K; Tan SM; Cox AJ; Advani A; Connelly KA; Whiteside CI; Gilbert RE
    Nephrol Dial Transplant; 2009 Jun; 24(6):1782-90. PubMed ID: 19155535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
    Nakamura S; Chikaraishi Y; Tsuruma K; Shimazawa M; Hara H
    Exp Eye Res; 2010 Jan; 90(1):137-45. PubMed ID: 19825373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase Cβ inhibition and renin-angiotensin system blockade: a pilot study.
    Cherney DZ; Reich HN; Scholey JW; Lai V; Slorach C; Zinman B; Bradley TJ
    Can J Physiol Pharmacol; 2012 Jan; 90(1):113-21. PubMed ID: 22188532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats.
    Bursell SE; Takagi C; Clermont AC; Takagi H; Mori F; Ishii H; King GL
    Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2711-20. PubMed ID: 9418723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
    PKC-DRS Study Group
    Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.